Crane Company (CR) Stock Price & How to Invest

Crane Company became a standalone public company in April 2023 when Crane Holdings separated into two businesses, with the industrial operations listing as CR (the payments-and-authentication side became Crane NXT). The company runs two segments: Aerospace & Advanced Technologies, which supplies power conversion, actuation, sensing and thermal-management systems for commercial aircraft, military platforms and space, and Process Flow Technologies, which makes valves, pumps, instrumentation and cryogenic systems for chemical, pharmaceutical, water and energy customers.

The investment picture centers on durable demand in both aerospace and process markets, a growing backlog, and a disciplined bolt-on acquisition strategy (recent deals include the Precision Sensors & Instrumentation assets bought from Baker Hughes for roughly $1.06 billion, adding the Druck, Panametrics, Reuter-Stokes and optek-Danulat brands). Crane pairs mid-single-digit organic growth with margin expansion and steady capital returns, but it trades at a premium multiple that already reflects a lot of that optimism, so results and integration execution matter.

Crane trades at a premium valuation (around 30 times earnings), so any slowdown in growth or margin misstep could pressure the stock. Reported GAAP EPS fell sharply in Q1 2026 on acquisition-related charges, and integrating deals like the Baker Hughes assets carries execution risk. Guidance assumes a possible decline in the high-margin commercial aerospace aftermarket, citing elevated oil prices and Middle East travel disruptions. The Process Flow business is cyclical and exposed to chemical, energy and industrial capital spending. Defense revenue depends on government budgets and program timing.

9 analysts publish price targets on CR, averaging $233.89 against a $213.46 price as of August 2026, or +9.6%. The published targets run from $192.00 to $253.00, a narrow spread, and the ratings split 8 buy, 1 hold, 0 sell. Over the last six months there have been 3 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Crane Company. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Aerospace and defense demand. The Aerospace & Advanced Technologies segment grew sales roughly 28% year over year in Q1 2026 to about $318 million, supported by commercial aircraft build rates, a large defense and space backlog, and high-margin aftermarket revenue. The most optimistic published target, $253.00, assumes this works close to its best case.

The case against. Crane trades at a premium valuation (around 30 times earnings), so any slowdown in growth or margin misstep could pressure the stock. The most pessimistic target, $192.00, is roughly what CR is worth if this bites instead.

Read the full bull and bear case on CR, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Crane Company's investor relations page or your broker.

• Revenue (TTM): ~$2.5B
• Q1 2026 revenue: ~$696M (+25% YoY)
• Adjusted EPS (Q1 2026): ~$1.65 (+15% YoY)
• FY2026 adjusted EPS guidance: ~$6.65 to $6.85
• Market cap: ~$12B
• P/E ratio: ~31x

Crane reported roughly 25% net-sales growth in Q1 2026 (about 4% organic plus acquisitions) and raised full-year adjusted EPS guidance. Adjusted operating margin was near 19.8% while GAAP EPS declined on acquisition-related items. The shares carry a premium multiple around 30 times earnings, reflecting expectations for continued growth.

Other names that sit close to CR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CR is an aerospace-and-industrial growth story riding strong defense and commercial demand, priced at a premium multiple that leaves little room for execution missteps.

Whether CR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CR a buy or a sell?, and where the stock could go from here in the CR stock forecast.

For income investors, whether CR pays a dividend and how the payout looks is covered in does CR pay a dividend? And to weigh CR against a peer, read the full side-by-side comparisons: CR vs WWD and CR vs PH.